BLOG OLD

The People Behind the Process: How Resilience’s Teams Enable Flexible Biopharma Manufacturing

Resilience — Wed, 30 Sep 2026 17:18:19 GMT

The Future of CDMOs: Navigating the Combinations Interview with Kothari and Jonathon Amaya-Hodges

Resilience — Thu, 27 Aug 2026 13:25:46 GMT

On Demand Webinar: Outsourced Pharma Capabilities Update - Large Molecule

Resilience — Wed, 05 Aug 2026 18:02:06 GMT

Looking for a large molecule manufacturing partner with the capacity and capabilities to support your program today? You have come to the right place.

From Complexity to Clarity - Sharpening Focus for Long-Term Performance in a More Demanding CDMO Era

Resilience — Thu, 14 May 2026 20:26:14 GMT

Published by Drug Development & Delivery

Resilience has spent the past year reshaping its business with a clear objective: sharpen focus, strengthen execution, and deliver with consistency. In this interview, Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.

She also points to a broader shift across the CDMO landscape, where accountability, selectivity, and operational rigor are taking center stage. In this environment, Resilience is positioning itself as a dependable, long-term partner, built to meet rising expectations for performance, reliability, and scale.

Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy

Resilience — Thu, 20 Nov 2025 15:38:03 GMT

New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations

CINCINNATI--(BUSINESS WIRE)--National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced long-term debt financing of up to $825 million from Oak Hill Advisors (“OHA”) to strengthen its balance sheet and fuel its growth plans. This new capital will enable Resilience to accelerate its CDMO business strategy and invest in its go-forward manufacturing operations anchored in Cincinnati and Toronto.

This financing underscores Resilience’s critical role as a CDMO manufacturing sterile drugs at scale and on shore. OHA brings more than three decades of investment experience and a proven track record of supporting growth in the life sciences sector. Resilience remains focused on high-growth segments in the biopharmaceutical market to advance cell-based medicines, primarily biologics, and aseptic drug product operations. The company is in the process of expanding its Cincinnati facility into one of the largest, most advanced sterile injectable and device assembly and packaging operations in North America.

William S. Marth, President and Chief Executive Officer of Resilience, said, “This financing is a pivotal step forward for our enterprise and positions us well to advance our ongoing transformation efforts backed by favorable industry tailwinds in the CDMO sector. This new capital will support the continued buildout of our core manufacturing operations and enable us to serve our customers with stability and excellence into the future, particularly at a time when pharmaceutical onshoring is a national priority. Partnering with OHA and our supportive long-time shareholders, we are confident that Resilience now has the right focus, footprint and financial profile to capitalize on the exciting strategic growth opportunities ahead.”

“We believe Resilience is uniquely positioned to scale its advanced manufacturing capabilities and meet the increasing demand for complex medicines,” said Joe Goldschmid, Managing Director at OHA. “Our investment reflects conviction in the company’s leadership team, strategic positioning and ability to generate long-term value in a sector undergoing rapid transformation. We look forward to supporting Resilience as it expands its footprint and strengthens its role in the global biomanufacturing ecosystem.”

The financing includes a $600 million first lien commitment from OHA. The initial tranche of $525 million is expected to be funded later in the fourth quarter, with the remainder of the financing in subsequent years as needed. Financing is subject to satisfaction of customary conditions.

In addition to obtaining the new term loan, Resilience has successfully resolved the lease obligations related to its underutilized sites, further optimizing its balance sheet.

Jefferies LLC is serving as financial advisor and Kirkland & Ellis LLP is serving as legal counsel to Resilience on the financing transaction.

About Resilience
Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably. The company is building a streamlined, high-performance network designed to meet the evolving needs of clinical and commercial-stage innovators. For more information follow us on social media: Resilience on LinkedIn.

About Oak Hill Advisors
Oak Hill Advisors (OHA) is a leading global credit-focused alternative asset manager with over 30 years of investment experience. OHA works with institutions and individuals and seeks to deliver a consistent track record of attractive risk-adjusted returns. The firm has approximately $98 billion in assets under management (AUM) across credit strategies, including private credit, distressed and special situation investments, high yield bonds, leveraged loans and collateralized loan obligations as of June 30, 2025. Additional information on OHA’s AUM calculation methodology can be found on the OHA website. OHA’s emphasis on long-term partnerships with companies, sponsors and other partners allows for the provision of customized credit solutions across market cycles.

With over 420 experienced professionals across six global offices, OHA brings a collaborative approach to offering investors a single platform to meet their diverse credit needs. OHA is the private markets platform of T. Rowe Price Group, Inc. (NASDAQ – GS: TROW). For more information, please visit www.oakhilladvisors.com.

Media Contacts:

For Resilience:

Kekst CNC
ResilienceMedia@kekstcnc.com

Catherine Hanley
Vice President, Corporate Communications
Resilience
catherine.hanley@resilience.com

For OHA:

Natalie Harvard
Head of Investor Relations & Partner
(212) 326-1505
nharvard@oakhilladvisors.com

Redefining CAR-T Speed and Strength with DAR-T™: A Conversation with Nicholas Kirian

Resilience — Thu, 20 Nov 2025 14:49:14 GMT

In this Q&A, Nicholas Kirian, Senior Manager of MSAT, discusses how DAR-T™, an autologous CAR-T platform, is addressing longstanding challenges in cell therapy manufacturing. From reducing cycle times to improving cell potency and persistency, DAR-T is redefining what is possible in the production of life-saving therapies.

How integrated data systems enhance clinical development and manufacturing

Resilience — Fri, 11 Jul 2025 15:13:04 GMT

Published by PharmaVoice

In the rapidly evolving landscape of biopharmaceuticals, the integration of robust digital systems has become paramount. Companies have more digital systems than ever before, but when these systems are disconnected from one another, it detracts from the efficient coordination needed to bring new innovative therapies to the market. As the demand for development & manufacturing services surges for complex medicines such as cell therapies, biologics, and sterile injectables, it necessitates agile, transparent, and data-rich manufacturing environments.

CDMOs Are Making Their Supply Chains More Resilient & Secure

Resilience — Fri, 27 Jun 2025 15:23:06 GMT

Published byDrug Development & Delivery

Growing R&D activities, personalized medicines, large-scale production of biologics, and access to new technologies are some of the biggest reasons why the contract development and manufacturing organization (CDMO) market is expected to practically double from $168 billion this year to $318 billion by 2034.1

Navigating the Evolving Landscape of Fill/Finish: Trends, Challenges, and What’s Ahead

Resilience — Thu, 05 Jun 2025 18:19:41 GMT

A Q&A with Nithin Stephen

As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities has never been greater. From the pandemic-driven surge in vaccine production to the current boom in GLP-1 therapeutics, CDMOs are playing an increasingly critical role in supporting the delivery of complex medicines.

On Demand Webinar: Fill/Finish Services - Outsourced Pharma Capacity Update

Resilience — Thu, 08 May 2025 14:38:06 GMT

Seeking an experienced fill/finish partner with available capacity today? You have come to the right place.